熱門資訊> 正文
凯罗斯制药（Kairos Pharma）IPO定价620万美元
2024-09-16 23:19
- Kairos Pharma (NYSEMKT:KAPA) priced on Monday its initial public offering of 1.5M shares of common stock at a public offering price of $4 per share.
- The gross proceeds from the offering are expected to be $6.2M.
- Kairos Pharma (KAPA) intends to use the net proceeds from the offering to fund its Phase 1 trial in lung cancer and Phase 2 trial in prostate cancer for its lead product candidate ENV 105.
- The company’s common stock has been approved for listing on the NYSE American and trading is expected to begin on September 16, 2024 under the symbol “KAPA.”
More on Kairos Pharma, Ltd.
- IPO Roundup: Bicara Therapeutics, Kairos Pharma and more
- Financial information for Kairos Pharma, Ltd.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
